Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ablynx NV (OTC: ABLYF).

Full DD Report for ABLYF

You must become a subscriber to view this report.


Recent News from (OTC: ABLYF)

Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Source: SeekingAlpha
Date: May, 02 2018 08:00
Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV
Ablynx ( OTCPK:ABLYF ) completes enrollment of 180 infants in a Phase 2b clinical trial, RESPIRE , assessing inhaled drug candidate ALX-0171 for the treatment of respiratory syncytial virus (RSV) infection. More news on: Ablynx NV, Sanofi, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 30 2018 07:43
Ablynx's vobarilizumab flunks mid-stage lupus study
Ablynx's ( OTCPK:ABLYF ) vobarilizumab failed to demonstrate a dose response after 24 weeks of treatment in a Phase 2 dose-ranging study in patients with moderate-to-severe active seropositive systemic lupus erythematosus (SLE). More news on: Ablynx NV, Healthcare stocks news, Read m...
Source: SeekingAlpha
Date: March, 26 2018 08:15
Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV
Dosing is underway in a Japan-based Phase 2 clinical trial evaluating Ablynx's ( OTCPK:ABLYF ) ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections. More news on: Ablynx NV, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 02 2018 09:31
Ablynx NV reports FY results
Ablynx NV ( OTCPK:ABLYF ): FY Net loss of €108.5M Revenue of €55.5M (-34.9% Y/Y) Press Release More news on: Ablynx NV, Ablynx NV, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: February, 22 2018 03:35
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofi’s ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued ...
Source: SeekingAlpha
Date: January, 30 2018 08:00
Ablynx: Novo Offer Undervalues The Company
We first covered Ablynx ( OTCPK:ABLYF ) in September 2017, ahead of an important catalyst for the company. The note was published ahead of the data readout from the phase 3 HERCULES study. We had noted that ABLYF was a buy ahead of the event. The event played out as expected and ABLYF shares...
Source: SeekingAlpha
Date: January, 22 2018 10:00
Your Daily Pharma Scoop: Ablynx Takeover Battle, Acorda Takeover Speculation, Oramed Update
Analysis of top Seeking Alpha coverage: Ablynx ( ABLYF ) Today, we will discuss the ongoing takeover battle involving Novo Nordisk ( NVO ) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions...
Source: SeekingAlpha
Date: January, 20 2018 07:59
Novo Nordisk: Don't Spoil The Ablynx Acquisition
Novo Nordisk's bid on Ablynx On January 8, 2017, Novo Nordisk ( NVO ), the Danish multinational pharmaceutical giant, made a public announcement that it wanted to acquire the Belgian biotech company Ablynx ( ABLX ) ( ABLYF ). Novo Nordisk offered $33 per share, which means a total amount ...
Source: SeekingAlpha
Date: January, 17 2018 15:16
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered ...
Source: SeekingAlpha
Date: January, 09 2018 11:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-11N/A50.63N/AN/A0
2018-12-10N/A50.63N/AN/A0
2018-12-07N/A50.63N/AN/A0
2018-12-06N/A50.63N/AN/A0
2018-12-05N/A50.63N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-02-1573078093.5897Short
2018-02-07202580.0000Short
2018-02-061,7003,70045.9459Short
2018-02-0110050020.0000Cover
2018-01-3110010199.0099Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABLYF.


About Ablynx NV (OTC: ABLYF)

Logo for Ablynx NV (OTC: ABLYF)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck amp Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

 

Current Share Structure

  • Market Cap: $2,363,440,092 - 03/16/2018
  • Issue and Outstanding: 43,689,900 - 09/30/2011

 


Recent Filings from (OTC: ABLYF)

Amendment to a previously filed SC 14D9
Filing Type: SC 14D9/AFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: May, 14 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: May, 07 2018
Amendment to a previously filed SC 14D9
Filing Type: SC 14D9/AFiling Source: edgar
Filing Date: May, 07 2018
Amendment to a previously filed 20-F
Filing Type: 20-F/AFiling Source: edgar
Filing Date: April, 05 2018
Solicitation/recommendation statements
Filing Type: SC 14D9Filing Source: edgar
Filing Date: April, 04 2018
Tender offer schedule and amendment filed by a third party
Filing Type: SC TO-TFiling Source: edgar
Filing Date: April, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 29 2018
Written public communication relating to an issuer or third party tender offer not by the subject company
Filing Type: SC TO-CFiling Source: edgar
Filing Date: March, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (OTC: ABLYF)

Daily Technical Chart for (OTC: ABLYF)


Stay tuned for daily updates and more on (OTC: ABLYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ABLYF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABLYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABLYF and does not buy, sell, or trade any shares of ABLYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/